Conexeu Sciences has opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre in Vancouver, expanding the operational base for its CXU regenerative tissue platform. The company, which is preclinical-stage, is designing the single-technology platform to scale across soft-tissue restoration markets, with aesthetics and body contouring increasingly at the center of its direction. The facility will support advancement of the CXU platform and its lead device candidate, Ten-Minute Tissue, a thermosensitive material designed to be injected as a liquid and set into a stable gel at body temperature. Conexeu is targeting the aesthetics opportunity created by GLP-1 therapies, a market it estimates is heading toward roughly $2 billion by 2030, and anticipates a 510(k) submission in wound care in early 2027. The same platform also extends to wound care, periodontal applications, and a 3D-bioprinted breast matrix program called B.R.E.A.S.T.
Conexeu Sciences Inc. Common StockOpened new R&D lab to advance regenerative tissue platform and lead device candidate Ten-Minute Tissue
AbbVie Inc
Eli Lilly and Company
Establishment Labs Holdings Inc